Life-Threatening Acute Pancreatitis Associated with Interferon Beta-1a Treatment in Multiple Sclerosis
Neurol 65:170-171, Midgard,R.,et al, 2005
Statin Use and the Risk of Incident Dementia
Arch Neurol 62:1047-1051, Rea,T.D.,et al, 2005
Pregnancy Outcomes During Treatment with Interferon Beta-1a in Patients with Multiple Sclerosis
Neurol 65:802-806, Sandberg-Wollheim,M.,et al, 2005
The Reproductive Effects of Beta Interferon Therapy in Pregnancy, A longitudinal Cohort
Neurol 65:807-811,788, Boskovic,R.,et al, 2005
Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90056 Participants in 14 Randomised Trials of Statins
Lancet 366:1267-1278, Cholesterol Treatment Trialists (CTT) Collaborators, 2005
Infliximab and Reactivation of Cerebral Toxoplasmosis
NEJM 353:1530-1531, Callegari,P.E., 2005
Statins Are Associated With Better Outcomes After Carotid Endarterectomy in Symptomatic Patients
Stroke 36:2072-2076,2058, Kennedy,J.,et al, 2005
Oligophrenin 1 Mutations Frequently Cause X-Linked Mental Retardation with Cerebellar Hypoplasia
Neurol 65:1364-1369,1346, Zanni,G.,et al, 2005
Statins and Cognitive Functioning the Elderly
Neurol 65:1388-1394, Bernick,C.,et al, 2005
Rhabdomyolysis: An Evaluation of 475 Hospitalized Patients
Medicine 84:377-385, Melli,G.,et al, 2005
Lipid Lowering Agents Are Associated With a Slower Cognitive Decline in Alzheimers Disease
JNNP 76:1624-1629, Masse,I.,et al, 2005
Efficacy of TNF a Blockade in Cyclophosphamide Resistant Neuro-Behet Disease
JNNP 76:1733-1735, Ribi,C.,et al, 2005
Two Patients With COMT Inhibitor-Induced Hepatic Dysfunction and UGT1A9 Genetic Polymorphism
Neurol 65:1820-1822, Martignoni,E.,et al, 2005
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
NT-3 Promotes Nerve Regeneration and Sensory Improvement in CMT1A Mouse Models and in Patients
Neurol 65:681-689, 662, Sahenk,Z.,et al, 2005
Lipid-Lowering Agent Use at Ischemic Stroke Onset is Associated with Decreased Mortality
Neurol 65:253-258, Elkind,M.S.V.,et al, 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Cholinesterase Inhibitors for Patients with Alzheimers Disease: Systematic Review of Randomised Clinical Trials
BMJ 331:321-323, Kaduszkiewicz,H.,et al, 2005
Phaeochromocytoma
Lancet 366:665-675, Lenders,J.W.M.,et al, 2005
Salvage Therapy for Primary CNS Lymphoma with a Combination of Rituximab and Temozolomide
Neurol 63:901-903, Enting,R.H.,et al, 2004
Monoamine Oxide Type B Inhibitors in Early Parkinson's Disease:Meta-Analysis of 17 Randomised Trials Involving 3525 Patients
BMJ 329:593-596, Ives,N.J.,et al, 2004
Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 364:1489-1496,1463, Filippi,M.,et al, 2004
Donepezil Improved Memory in Multiple Sclerosis in a Randomized Clinical Trial
Neurol 63:1579-1585, Krupp,L.B.,et al, 2004
Interferon beta-1b in Secondary Progressive MS
Neurol 63:1779-1787,1768, Kappos,L.,et al, 2004
Interferon beta-1b in Secondary Progressive MS
Neurol 63:1788-1795,1768, The North American Study Group on Interferon beta-, 2004
Clomipramine Induced Neuroleptic Malignant Syndrome and Pyrexia of Unknown Origin
BMJ 329:1333-1335, Haddow,A.M.,et al, 2004
Sibutramine May Be Associated With Memory Impairment
BMJ 329:1316, Clark,D.W.J. &Harrison-Woolrych,M., 2004
Rivastigmine for Dementia Associated with Parkinson's Disease
NEJM 351:2509-2518,2547, Emre,M.,et al, 2004
Anticoagulants for Acute Ischemic Stroke
Stroke 35:2916-2917, Sandercock,P.,et al, 2004
Statins in Stroke Prevention and Carotid Artherosclerosis, Systematic Review and Up-to-Date Meta-Analysis
Stroke 35:2902-2909, Amarenco,P.,et al, 2004
Incidence of Hospitalized Rhabdomyloysis in Patients Treated With Lipid-Lowering Drugs
JAMA 292:2585-2590, Graham,D.J.,et al, 2004
Statin-Associated Exacerbation of Myasthenia Gravis
Neurol 63:2188, Cartwright,M.S.,et al, 2004
Oral Simvastin Treatment in Relapsing-Remitting Multiple Sclerosis
Lancet 363:1607-1608,1570, Vollmer,T.,et al, 2004
Hypercholesterolemia, HMG-CoA Reductase Inhibitors, and Risk of Intracerebral Hemorrhage
Stroke 35:1360-1364, Woo,D.,et al, 2004
Direct Thrombin Inhibition
Stroke 35:1519-1522, Elkind,M.S.V. &Sacco,R.L., 2004
Fatal Myositis Due to the Microsporidian Brachiola algerae, a Mosquito Pathogen
NEJM 351:42-47, Coyle,C.M.,et al, 2004
Alzheimer's Disease
NEJM 351:56-67, Cummings,J.L, 2004
The Efficacy of Donepezil in the Treatment of Neuropsychiatric Symptoms in Alzheimer Disease
Neurol 63:214-219,200, Holmes,C.,et al, 2004
Stalevo for Parkinson's Disease
The Medical Letter 46:39, , 2004
Long-term Donepezil Treatment in 565 Patients with Alzheimer's Disease (AD2000): Randomised Double-Blind Trial
Lancet 363:2105-2115,2100, AD2000 Collaborative Group, 2004
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Economic Evaluation of Donepezil in Moderate to Severe Alzheimer Disease
Neurol 63:644-650, Feldman,H.,et al, 2004
Efficacy of Donepezil in Mild Cognitive Impairment
Neurol 63:651-657, Salloway,S.,et al, 2004
Reduced Risk of Alzheimer Disease in Users of Antioxidant Vitamin Supplements
Arch Neurol 61:82-88, Zandi,P.P.,et al, 2004
Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil, A Randomized Controlled Trial
JAMA 291:317-324, Tariot,P.N.,et al, 2004
Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004
Effects of Cholesterol-lowering with Simvastatin on Stroke and Other Major Vascular Events in 20 536 People with Cerebrovascular Disease or Other High-Risk Conditions
Lancet 363:757-767, Heart Protection Study Collaborative Group, 2004
Therapy for Nerve Agent Poisoning
Arch Neurol 61:649-652, Newmark,J., 2004
Favorable Outcome of Ischemic Stroke in Patients Pretreated with Statins
Stroke 35:1117-1123, Marti-Fabregas,J.,et al, 2004
Size of the Treatment Effect on Cognition of Cholinesterase Inhibition in Alzheimer's Disease
JNNP 75:677-685, Rockwood,K., 2004